A study of the changes in the level of serum IgG4 antibody and soluble CD23 (s-CD23) in nasal allergy patients with immunotherapy.
Specific IgG4 antibodies were determined by enzyme-linked immunosorbent assay (ELISA), radio allergosorbent test (RAST), and s-CD23 in a total of 17 patients with nasal allergy who were given immunotherapy with house dust. The following results were obtained. 1) From the results between the serum antigen-specific IgG4 and the clinical effect of immunotherapy, there are many cases showing the elevation of antigen-specific IgG4 antibody titer. But in the elevated cases, there were only 7 cases showing good and excellent responses in a clinical effect of 41.1%. 2) IgG4 antibody was gradually elevated in many cases during immunotherapy, but in a few cases, abruptly increased after the maximum tolerated dose was established. 3) Regarding the outcome between IgG4 antibody and IgE antibody, cases of rising IgG4 and decreasing IgE occurred at a rate of 41%. 4) s-CD23 in sera gradually decreased in many cases during immunotherapy, but in a few cases, did not change.
Ito
H
H
Department of Otorhinolaryngology, School of Medicine, Nagoya City University, Japan.
Nishimura
J
J
Mamiya
S
S
Suzuki
M
M
Yokota
A
A
Baba
S
S
D000293:Adolescent; D000328:Adult; D000818:Animals; D000941:Antigens / Q000276:immunology / Q000627:therapeutic use; D002648:Child; D003888:Desensitization, Immunologic; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood*; D008297:Male; D008925:Mites / Q000276:immunology; D017455:Receptors, IgE / Q000032:analysis*; D012221:Rhinitis, Allergic, Perennial / Q000276:immunology* / Q000628:therapy
D000941:Antigens; D007074:Immunoglobulin G; D017455:Receptors, IgE; D007073:Immunoglobulin E